Clinical Trial

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2023-06-13; most recent amendment 2025-11-18.
Status change: Not Yet Recruiting → Recruiting 2023-09-08
Trial Details
NCT Number NCT05914116
Lead Sponsor DualityBio Inc.
Collaborators: BioNTech SE
Conditions Advanced Solid Tumors
Enrollment 862 participants
Start Date 2023-08-17
Primary Completion 2027-12 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2025-11-21